Antitumor and Antimetastatic Activity of Interleukin 12 against Murine Tumors

Journal of Experimental Medicine

Volumn 178, Issue 4, 1993, Pages 1223-1230

  Brunda, Michael J ^a   Luistro, Leopoldo ^a   Warrier, Rajeev R ^a   Wright, Rosemary B ^a   Hubbard, Brian R ^b   Murphy, Molly ^b   Wolf, Stanley F ^b   Gately, Maurice K ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 12;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; INTERFERON PRODUCTION; MELANOMA; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RETICULOSARCOMA; SURVIVAL TIME; TUMOR;

ANIMAL; ANTINEOPLASTIC AGENTS; CHO CELLS; HAMSTERS; INTERLEUKIN-12; INTERLEUKINS; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0027239503     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.178.4.1223     Document Type: Article

References (35)

1. Kobayashi, M., L. Fitz, M. Ryan, R.M. Hewick, S.C. Clark, S. Chan, R. Loudon, F. Sherman, B. Ferussia, and G. Trin-chieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp Med. 170:827.
2. Stem, A.S., F.J. Fodlaski, J.D. Hulmes, Y.E. Pan, P.M. Quinn, A.G. Wolitzky, P.C. Familletti, D.L. Stremlo, T. Truitt, R. Chizzonite, and M.K. Gately. 1990. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl. Acad. Set. USA. 87:6808.
3. Wolf, S.F., P.A. Temple, M. Kobayashi, D. Young, M. Dicig, L. Lowe, R. Dzialo, L. Fitz, D. Ferenz, R.M. Hewick, et al. 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biological effects on T and natural killer cells. /. Immunol. 146:3074.
4. Gubler, U., A.O. Chua, D.S. Schoenhaut, C.M. Dwyer, W. McComas, R. Motyka, N. Nabavi, A.G. Wolitzky, P.M. Quinn, P.C. Familletti, and M.K. Gately. 1991. Coexpression of two distinct genes is required to generate secreted, bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA. 88:4143.
5. Gately, M.K., B. Desai, A.G. Wolitzky, P.M. Quinn, C.M. Dwyer, F.J. Podlaski, P.C. Familletti, F. Sinigaglia, R. Chizzonite, U. Gubler, and A.S. Stern. 1991. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. 147:874.
6. + T lymphocytes, and NK cells. J. Immunol. 149:3495.
7. Robertson, M.J., R.J. Soiffer, S.F. Wolf, T.J. Manley, C. Donahue, D. Young, S.H. Herrmann, and j. Ritz. 1992. Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp Med. 175:779.
8. + NK cells./. Immunol. 148:2429.
9. Gately, M.K., A.G. Wolitzky, P.M. Quinn, and R. Chizzonite. 1992. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell. Immunol. 143:127.
10. Chan, S.H., R Perussia, J.W. Gupta, M. Kobayashi, M. Pospisil, H.A. Young, S.F. Wolf, D. Young, S.C. Clark, and G. Trinchieri. 1991. Induction of interferon y production by natural killer cell stimulatory factor: characterization of the responding cells and synergy with other inducers./. Exp Med. 173:869.
11. Kedar, E., and E. Klein. 1992. Cancer immunotherapy: are the results discouraging? Can they be improved? Adv. Cancer Res. 59:245.
12. Brunda, M.J., V. Sulich, and D. Bellantoni. 1987. The antitumor effect of recombinant interferon alpha and gamma is influenced by tumor location. Int. J. Cancer. 40:807.
13. Truitt, G.A., J.M. Bontempo, L.L. Stem, V. Sulich, D. Bellantoni, P.W. Trown, and M.J. Brunda. 1989. Efficacy and toxicity elicited by recombinant interferons alpha and gamma when administered in combination to tumor-bearing mice. Biotechnol. Ther. 1:1.
14. Schoenhaut, D.D., A.O. Chua, A.G. Wolitzky, P.M. Quinn, C.M. Dwyer, W. McComas, P.C. Familletti, M.K. Gately, and U. Gubler. 1992. Cloning and expression of murine IL-12. /. Immunol. 148:3433.
15. Brunda, M.J., D. Rosenbaum, and L. Stem. 1984. Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases. Int. J. Cancer. 34:421.
16. Salup, R.R., T.C. Back, and R.H. Wiltrout. 1987. Successful treatment of advanced murine renal cell cancer by bicompart-mental adoptive chemoimmunotherapy./. Immunol. 138:641.
17. Brunda, M.J., D. Bellantoni, and V. Sulich. 1987. In vivo antitumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer. 40:365.
18. Gately, M.K., and R. Chizzonite. 1992. Measurement of human and mouse interleukin 12. In Current Protocols in Immunology, Vol. 1. J.E. Coligan, A.M. Kruisbeek, D.H. Mar-gulies, E.M. Shevach, and W. Strober, editors. John Wiley & Sons Inc., New York. 1-18.
19. Wilde, D.B., P. Marrack, J. Kappler, D.P. Dialynas, and F.W. Fitch. 1983. Evidence implicating L3T4 in class II MHC antigen reactivity: monoclonal antibody GK1.5 (anti-L3T4) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J. Immunol. 131:2178.
20. Sarmiento, M., A.L. Glasebrook, and F.W. Fitch. 1980. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement./. Immunol. 125:2665.
21. Reik, L.M., S.L. Maines, D.R. Ryan, W. Levin, S. Bandiera, and P.L. Thomas. 1987. A simple, chromatographic purification procedure for monoclonal antibodies. Isolation of monoclonal antibodies against cytochrome P450 isozymes. /. Immunol. Methods. 100:123.
22. Golumbek, P.T., A.J. Lazenby, H.I. Levitsky, L.M. Jaffee, H. Karasuyama, M. Baker, and D.M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Wash. DC). 254:713.
23. Roder, J.C., M.-L. Matthes, W. Domzig, and H.J. Wigzell. 1979. The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. /. Immunol. 123:2174.
24. Brunda, M.J., and R.B. Wright. 1986. Differential antiproliferative effects of combinations of recombinant interferons alpha and gamma on two murine tumor cell lines. Int.J. Cancer. 37:287.
25. Bucy, R.P., D.W. Hanto, E. Berens, and R.W. Schreiber. 1988. Lack of an obligate role for IFN-y in the primary in vitro mixed lymphocyte response. /. Immunol. 140:1148.
26. Giovarel U. M., A. Santoni, C. Jemma, T. Musso, M.A. Giuffrida, G. Cavallo, S. Landolfo, and G. Forni. 1988. Obligatory role of IFN-y in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity./ Immunol. 141:2831.
27. Dalton, D.K., S. Pitts-Meek, S. Keshav, I.S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-y genes. Science (Wash. DC). 259:1739.
28. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411.
29. Tripp, C.S., S.F. Wolf, and E.R. Unanue. 1993. Interleukin 12 and tumor necrosis factor a are costimulators of interferon 7 production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl. Acad. Sci. USA. 90:3725.
30. Mulé, J.J., J.C. Yang, R. Lafreniere, S. Shu, and S.A. Rosenberg. 1987. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary métastasés by systemic administration of high-dose recombinant interleukin-2. J. Immunol. 139:285.
31. + T cell-dependent tumor rejection. J. Exp Med. 174:1291.
32. + T cells through IL-12 produced by Listeria-induced macrophages. Science (Wash. DC). 260:547.
33. Manetti, R., P. Parronchi, M.G. Giudizi, M.-P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Thl)-specific immune response and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199.
34. Baron, S., S.K. Tyring, W.R. Fleichmann, Jr., D.H. Coppen-haver, D.W. Niesei, G.R. Klimpel, G.J. Stanton, and T.K. Hughes. 1991. The interferons. Mechanisms of action and clinical application. J. Am. Med. Assoc 266:1375.
35. Rosenberg, S.A., M.T. Lotze, L.M. Muul, A.E. Chang, F.P. Avis, S. Leitman, W.M. Linehan, C.N. Robertson, R.E. Lee, J.T. Rubin, et al. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Eng. J. Med. 316:889